{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021555","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.226283+00:00","generated_at":"2026-05-16T22:18:10.059835+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harrow Q3 revenue $71.6M (+45% YoY), net income $1.0M; VEVYE revenue $22.6M (+22% QoQ)","bullets":["Total revenue $71.6M (+45% YoY); GAAP net income $1.0M vs loss $4.2M YoY; Adj. EBITDA $22.7M vs $8.8M","VEVYE revenue $22.6M (+22% QoQ); national DED market share 10.5% (up 2.7pp); coverage agreements with largest PBM effective Jan 2026","IHEEZO revenue $21.9M (+70% YoY); on track to exceed $50M annual revenue by year-end 2025","Agreed to acquire Melt Pharmaceuticals (MELT-300) for non-opioid sedation; refinancing cut interest ~$3M/yr, added $50M liquidity"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021555","json":"https://secwatch.observer/filing/0001493152-25-021555.json","markdown":"https://secwatch.observer/filing/0001493152-25-021555.md","text":"https://secwatch.observer/filing/0001493152-25-021555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315225021555/0001493152-25-021555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315225021555/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:18:10.059835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}